Updated clinical data from a phase Ib combination cohort evaluating vepdegestrant, an investigational oral proteolysis targeting chimera estrogen receptor degrader, in combination with palbociclib (Ibrance) are consistent with data presented at the San Antonio Breast Cancer Symposium in December 2023.
University of Pittsburgh and UPMC Hillman Cancer Center researchers have developed a novel prompt, or ‘nudge,’ embedded in the electronic health record that flags, for treating surgeons, older patients with early-stage breast cancer who may be at risk for unnecessary lymph node surgery.
